Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;27(12):1861.e1-1861.e5.
doi: 10.1016/j.cmi.2021.07.042. Epub 2021 Aug 8.

Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan

Affiliations

Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan

Takahiro Kageyama et al. Clin Microbiol Infect. 2021 Dec.

Abstract

Objectives: This study aimed to determine antibody responses in healthcare workers who receive the BNT162b2 mRNA COVID-19 vaccine and identify factors that predict the response.

Methods: We recruited healthcare workers receiving the BNT162b2 mRNA COVID-19 vaccine at the Chiba University Hospital COVID-19 Vaccine Center. Blood samples were obtained before the 1st dose and after the 2nd dose vaccination, and serum antibody titers were determined using Elecsys® Anti-SARS-CoV-2S, an electrochemiluminescence immunoassay. We established a model to identify the baseline factors predicting post-vaccine antibody titers using univariate and multivariate linear regression analyses.

Results: Two thousand fifteen individuals (median age 37-year-old, 64.3% female) were enrolled in this study, of which 10 had a history of COVID-19. Before vaccination, 21 participants (1.1%) had a detectable antibody titer (≥0.4 U/mL) with a median titer of 35.9 U/mL (interquartile range [IQR] 7.8 - 65.7). After vaccination, serum anti-SARS-CoV-2S antibodies (≥0.4 U/mL) were detected in all 1774 participants who received the 2nd dose with a median titer of 2060.0 U/mL (IQR 1250.0 - 2650.0). Immunosuppressive medication (p < 0.001), age (p < 0.001), time from 2nd dose to sample collection (p < 0.001), glucocorticoids (p = 0.020), and drinking alcohol (p = 0.037) were identified as factors predicting lower antibody titers after vaccination, whereas previous COVID-19 (p < 0.001), female (p < 0.001), time between 2 doses (p < 0.001), and medication for allergy (p = 0.024) were identified as factors predicting higher serum antibody titers.

Conclusions: Our data demonstrate that healthcare workers universally have good antibody responses to the BNT162b2 mRNA COVID-19 vaccine. The predictive factors identified in our study may help optimize the vaccination strategy.

Keywords: COVID-19; Healthcare worker; Immunogenicity; SARS-CoV-2; Vaccine.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Multivariate linear regression model to predict anti-SARS-CoV-2S antibody titers after vaccination. Shown are the variables retained in the final multivariate linear regression model to explain anti-SARS-CoV-2S antibody titers after vaccination. A dot and bar represent standardized coefficient β and 95% confidence interval for the variable.
Fig. S1
Fig. S1
Distribution of antibody titers: A, B. Boxplots for the distribution of anti-SARS-CoV-2S antibody titers. A box represents interquartile range and a horizontal line in a box represents median. A vertical line represents a range excluding outliers. A circle and an asterisk represent outlier and extreme outlier, respectively. A. Before and after vaccination, in subjects whose data are available (n = 1774). Undetectable titers (<0.4 U/mL) are imputed with a value of 0.4 U/mL before log-transformed. The age range is 21-72-year-old. B. After vaccination, according to age groups and sex.

References

    1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383:2603–2615. - PMC - PubMed
    1. Dagan N., Barda N., Kepten E., Miron O., Perchik S., Katz M.A., et al. BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384:1412–1423. - PMC - PubMed
    1. Hall V.J., Foulkes S., Saei A., Andrews N., Oguti B., Charlett A., et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021;397:1725–1735. - PMC - PubMed
    1. Dispinseri S., Secchi M., Pirillo M.F., Tolazzi M., Borghi M., Brigatti C., et al. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. Nat Commun. 2021;12:2670. - PMC - PubMed
    1. Lumley S.F., O’Donnell D., Stoesser N.E., Matthews P.C., Howarth A., Hatch S.B., et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N Engl J Med. 2021;384:533–540. - PMC - PubMed